Literature DB >> 12216109

Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells.

Hyuk-Joon Lee1, Eunsook Kim, Bokeun Jee, Jang-Hee Hahn, Kyuhyoung Han, Kyeong Cheon Jung, Seong Hoe Park, Hansoo Lee.   

Abstract

Earlier report showed that expression of a splice variant of CD99 transmembrane protein increases invasive ability of human breast cancer cells. Cell motility was also significantly enhanced by the CD99 splice variant expression. In an effort to identify the cellular components that mediate a signal transduction pathway triggered by the CD99 splice variant, known signal path inhibitors were examined for their effects on the motility of the CD99 splice variant-transfected MDA-MB-231 breast cancer cells. Phenylarsine oxide, an inhibitor of phosphatase specific for focal adhesion kinase, and PP1, an inhibitor of src kinase family, significantly suppressed motility of the cells. Among different types of src transfectant clones generated, kinase-negative mutant src transfectant cells were 80% less motile than the mock cells transfected with an empty-vector, while v-src and c-src transfectants exhibited cell motility levels at or slightly above the mock transfectant. These results suggest that src and focal adhesion kinase mediate the intracellular signaling pathway of a CD99 splice variant for the induction of motility of human breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12216109     DOI: 10.1038/emm.2002.26

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  8 in total

1.  Expression of CD99 in pleomorphic carcinomas of the lung.

Authors:  Seong-Ho Yoo; Jungho Han; Tae Jin Kim; Doo Hyun Chung
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

2.  CD99 acts as an oncosuppressor in osteosarcoma.

Authors:  Maria Cristina Manara; Ghislaine Bernard; Pier-Luigi Lollini; Patrizia Nanni; Monia Zuntini; Lorena Landuzzi; Stefania Benini; Giovanna Lattanzi; Marika Sciandra; Massimo Serra; Mario Paolo Colombo; Alain Bernard; Piero Picci; Katia Scotlandi
Journal:  Mol Biol Cell       Date:  2006-01-18       Impact factor: 4.138

3.  Immunohistochemical study of CD99 and EMA expression in ependymomas.

Authors:  Soheir Mahfouz; Ahmad Abdel Aziz; Samia M Gabal; Samar el-Sheikh
Journal:  Medscape J Med       Date:  2008-02-19

4.  Association of CD99 short and long forms with MHC class I, MHC class II and tetraspanin CD81 and recruitment into immunological synapses.

Authors:  Supansa Pata; Pavel Otáhal; Tomáš Brdička; Witida Laopajon; Kodchakorn Mahasongkram; Watchara Kasinrerk
Journal:  BMC Res Notes       Date:  2011-08-13

Review 5.  CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.

Authors:  Maria Cristina Manara; Michela Pasello; Katia Scotlandi
Journal:  Genes (Basel)       Date:  2018-03-13       Impact factor: 4.096

Review 6.  CD99 at the crossroads of physiology and pathology.

Authors:  Michela Pasello; Maria Cristina Manara; Katia Scotlandi
Journal:  J Cell Commun Signal       Date:  2018-01-06       Impact factor: 5.782

7.  CD99 Expression in Glioblastoma Molecular Subtypes and Role in Migration and Invasion.

Authors:  Lais C Cardoso; Roseli da S Soares; Talita de S Laurentino; Antonio M Lerario; Suely K N Marie; Sueli Mieko Oba-Shinjo
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

8.  Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.

Authors:  Vijaya Pooja Vaikari; Yang Du; Sharon Wu; Tian Zhang; Klaus Metzeler; Aarif M N Batcha; Tobias Herold; Wolfgang Hiddemann; Mojtaba Akhtari; Houda Alachkar
Journal:  Haematologica       Date:  2019-08-01       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.